Little Known Facts About ABBV-744 as a potential therapeutic option for aggressive cancers.
Participant eaten grapefruit or grapefruit products within three times just before the primary dose of study drug.88 These preclinical studies offer paradigms for foreseeable future clinical trials in AML, and using novel combinations of drugs is currently currently being investigated in clinical trials.In Section C, members will acquire ABBV-744 a